Gene Overexpression & Optimization
Dyadic has developed and continues to develop innovative tools for gene expression via its proprietary fungal host, Myceliopthora Thermophila (formerly classified as Chrysosporium lucknowense), or C1. This host organism is Dyadic’s premier system for the overexpression of genes and the production of proteins that until now have been difficult to express and produce in other systems.
Dyadic’s C1 overcomes the limitations of other host systems — such as bacteria and yeast — commonly used by industry for expressing genes from natural sources (see table 1). Unlike bacteria and yeast, C1 efficiently splices itrons and its glycosylation — or sugar structures — are similar to those observed in mammals.
Dyadic’s integrated C1 technology is primed for optimization of the host production organism as well as the manufacturing process. This creates a number of proven, differentiating advantages over current gene expression systems, including:
—Extremely efficient protein production and secretion
Protein yields from C1 are unprecedented in the industry.
—A variety of both inducible and constitutive promoters
Dyadic’s integrated gene expression system provides a variety of genetic switches to choose from, thus increasing the likelihood of successful expression.
—Varying host genetic backgrounds
Host strains with varying genetic backgrounds are currently in development, to ensure successful gene expression for each project’s objective. Whether the goal is to produce large amounts of protein inexpensively, or to produce a single protein in pure form, C1 has a host system that will be well suited for either target.
—Favorable growth conditions
C1 can grow and express proteins over a wide range of pH and temperature, allowing for gene expression under conditions optimal for the activity and stability of a wide range of targets. A particular advantage of C1 over other fungal expression systems is its ability to produce proteins at neutral pH, allowing for the production of proteins of physiological and biopharmaceutical interest.
F E R M E N T A T I O N C O N D I T I O N S —
Dyadic continues to develop and refine its gene expression technologies, achieving milestones and technology breakthroughs. Among the recent milestones is the high-level expression of a human gene for a biopharmaceutical product candidate; and the demonstration of a core glycosylation structure that is more “human-like” than those of yeasts and other fungi.
Dyadic believes that the unique properties of C1 will make it the premier system for the expression of genes essential to numerous industries.
Please visit Partnering Opportunities to find out how Dyadic can work with you to break the bottlenecks in your genomic research and development programs.